Statewide episode spending variation of thyroidectomy for lower-risk thyroid cancer.
코호트
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
2516 patients underwent thyroidectomy at 81 facilities.
I · Intervention 중재 / 시술
thyroidectomy for lower-risk thyroid cancer
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
The interaction between occurrence of post-operative complications and lengths of stay >2 nights contributed to dramatically higher spending. [CONCLUSIONS] Reducing complications and associated length of stay as well hospital readmissions represent opportunities to improve the value of thyroidectomy.
[BACKGROUND] This study aimed to evaluate variation in spending for thyroidectomy for patients with thyroid cancer.
- 연구 설계 cohort study
APA
Jensen CB, Xie S, et al. (2026). Statewide episode spending variation of thyroidectomy for lower-risk thyroid cancer.. American journal of surgery, 253, 116816. https://doi.org/10.1016/j.amjsurg.2025.116816
MLA
Jensen CB, et al.. "Statewide episode spending variation of thyroidectomy for lower-risk thyroid cancer.." American journal of surgery, vol. 253, 2026, pp. 116816.
PMID
41539038 ↗
Abstract 한글 요약
[BACKGROUND] This study aimed to evaluate variation in spending for thyroidectomy for patients with thyroid cancer.
[METHODS] This retrospective cohort study analyzed risk-adjusted, price-standardized Michigan-based claims data from 2015 to 2022 and included patients who underwent thyroidectomy for lower-risk thyroid cancer. The primary outcome was 90-day spending. A mixed linear model with facility as a random effect identified factors associated with spending variability.
[RESULTS] In total, 2516 patients underwent thyroidectomy at 81 facilities. Unadjusted 90-day spending ranged from $5917 to $25,630 across facilities (median $8993). Spending was lowest for lobectomy (median $7755) and highest for lobectomy followed by completion thyroidectomy (median $14,181). On regression, factors significantly associated with increased spending were patient age and readmission. The interaction between occurrence of post-operative complications and lengths of stay >2 nights contributed to dramatically higher spending.
[CONCLUSIONS] Reducing complications and associated length of stay as well hospital readmissions represent opportunities to improve the value of thyroidectomy.
[METHODS] This retrospective cohort study analyzed risk-adjusted, price-standardized Michigan-based claims data from 2015 to 2022 and included patients who underwent thyroidectomy for lower-risk thyroid cancer. The primary outcome was 90-day spending. A mixed linear model with facility as a random effect identified factors associated with spending variability.
[RESULTS] In total, 2516 patients underwent thyroidectomy at 81 facilities. Unadjusted 90-day spending ranged from $5917 to $25,630 across facilities (median $8993). Spending was lowest for lobectomy (median $7755) and highest for lobectomy followed by completion thyroidectomy (median $14,181). On regression, factors significantly associated with increased spending were patient age and readmission. The interaction between occurrence of post-operative complications and lengths of stay >2 nights contributed to dramatically higher spending.
[CONCLUSIONS] Reducing complications and associated length of stay as well hospital readmissions represent opportunities to improve the value of thyroidectomy.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Factors Associated with Receiving Thyroid Cancer Care From High-Volume Surgeons: Analysis of a State-Wide Claims Registry.
- The Effect of a Surgeon Communication Strategy on Treatment Preference for Thyroid Cancer: A Randomized Trial.
- Harnessing the Power of Physician Word Choice in Thyroid Cancer Treatment Decision-Making.
- The Fear Factor: How Cancer Recurrence Shapes Treatment Choices About Thyroid Cancer.
- Developing a large-scale quality improvement program for thyroid cancer surgery.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.